Research
Hormonal
GLP1, secreted from intestinal L-cells after meals, acts as an anorexigenic signal by activating GLP1 receptors in the hypothalamus and brainstem, inhibiting food intake via vagal afferents and central circuits.
GLP-1 is a hormone your gut releases after eating to help you feel full. Modern medications mimic this hormone to enhance its effect, leading to reduced appetite and weight loss. This works by acting on both the gut nerves and the brain.
StrongSupportsVERY_HIGH confidence
GLP1... is mainly secreted from intestinal L-cells... circulating GLP1 levels are high following a meal... central or site-specific administration of GLP1 or GLP1 analogs inhibits food intake in rodents... recent studies have provided evidence for a dual (peripheral and central) role of GLP1 in the suppression of appetite mediated by local vagal afferents and a gut–brain feedback mechanism.
Why this rating
Supported by extensive clinical and preclinical data, including the efficacy of GLP-1 agonists.
Source
Hypothalamic and brainstem neuronal circuits controlling homeostatic energy balance
Marc Schneeberger et al. · Journal of Endocrinology · 2013
DOI 10.1530/joe-13-0398
narrative_reviewCited 289×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Leptin acts as an anorexigenic signal by binding to LEPRb in the hypothalamus, activating the JAK2/STAT3 and PI3K pathways to stimulate POMC and inhibit AgRP neurons, thereby reducing food intake and increasing energy expenditure.Strong
- Ghrelin acts as an orexigenic signal by binding to GHSR on AgRP neurons in the arcuate nucleus, stimulating NPY and AGRP expression and increasing food intake and adiposity.Strong
- Insulin acts as an anorexigenic signal in the CNS by binding to insulin receptors in the hypothalamus, activating PI3K signaling to inhibit NPY and stimulate POMC, thereby reducing food intake.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →